CORDIS
EU research results

CORDIS

English EN

Translating molecular knowledge into early breast cancer management: building on the BIG (Breast International Group) network for improved treatment tailoring - TRANS-BIG

Project information

Grant agreement ID: 503426

  • Start date

    1 March 2004

  • End date

    28 February 2011

Funded under:

FP6-LIFESCIHEALTH

  • Overall budget:

    € 23 171 000

  • EU contribution

    € 7 000 000

Coordinated by:

BREAST INTERNATIONAL GROUP-AISBL

Belgium

Objective

A revolution in breast cancer care is likely as we move from empirical towards molecular oncology. For Europe to lead this revolution, the Breast International Group is planning a "sister" network of excellence -TRANS-BIG- dedicated to multinational translational research linked to prospective clinical trials. At the heart of TRANS-BIG is a large, non drug-oriented, molecular-based adjuvant trial for node negative patients, preceded by a validation/standardisation phase linking the genomic analysis of frozen tumour specimens to patient outcome. These exploratory and clinical studies intend, through DNA microarray gene expression, to identify patient subgroups that could be spared toxic/expensive adjuvant treatment. Such treatment tailoring for the highest incidence cancer in women might significantly decrease its economic burden. This trial aims to prospectively validate the 70-gene poor prognosis signature identified by Dutch researchers as a potentially better discriminator of outcome than traditional clinical/pathological factors. Additionally, traditional pathology analysis and bioinformatics/statistics will be centralised, contributing to standardisation/integration within the network. In light of rapidly evolving technologies, TRANS-BIG will ensure appropriate collection and storage of patient tumour/blood samples, allowing for future analysis such as proteomics and the development of user-friendly and commercially available tools in collaboration with several European SMEs. With a dedicated Ethical-Legal Committee TRANS-BIG will comply with all national/international regulations governing such research. Spreading of excellence will be achieved in partnership with Europa Donna and FECS, the latter coordinating a traineeship programme to provide opportunities for European researchers to acquire skills in breast cancer research/associated technologies.

Coordinator

BREAST INTERNATIONAL GROUP-AISBL

Address

Rue HÉGer-Bordet 1
Brussels

Belgium

Participants (43)

1ST MEDICAL FACULTYCHARLES UNIVERSITY AND GENERAL TEACHING HOSPITAL

Czechia

AGENDIA BV

Netherlands

CENTRE HOSPITALIER DE LUXEMBOURG

Luxembourg

DEPARTMENT OF ONCOLOGY, FINSEN CENTRE, RIGSHOSPITALET

Denmark

DEPARTMENT OF SURGERY - UNIVERSITY OF VIENNA

Austria

EUROPA DONNA - THE EUROPEAN BREAST CANCER COALITION

Italy

EUROPEAN CANCER ORGANISATION

Belgium

EUROPEAN ORGANISATION FOR THE RESEARCH AND TREATMENT OF CANCER

Belgium

FUNDACIO INSTITUT PER LA RECERCA VALL D'HEBRON

Spain

GRUPO ESPANOL DE ESTUDIO Y TRATAMIENTO tumourES SOLIDES

Spain

GRUPO ONCOLOGICO COOPERATIVO CHILENO DE INVESTIGACION

Chile

GRUPPO ONCOLOGICO ITALIANO DI RICERCA CLINICA

Italy

HELMHOLTZ ZENTRUM MÜNCHEN, GERMAN RESEARCH CENTER FOR ENVIRONMENTAL HEALTH

Germany

IMPERIAL COLLEGE OF SCIENCE, TECHNOLOGY AND MEDICINE

United Kingdom

INSTITUT GUSTAVE ROUSSY

France

INSTITUT JULES BORDET, CENTRE DES TUMEURS DE L'UNIVERSITÉ LIBRE DE BRUXELLES / ONCOLOGISCH CENTRUM ULB'

Belgium

INSTITUTE OF ONCOLOGY LJUBLJANA

Slovenia

INSTITUTE OF ONCOLOGY OF SOUTHERN SWITZERLAND

Switzerland

INSTITUTO DE PATOLOGIA E IMUNOLOGIA MOLECULAR DA UNIVERSIDADE DO PORTO

Portugal

INTERNATIONAL DRUG DEVELOPMENT INSTITUT SA

Belgium

ISTITUTO EUROPEO DI ONCOLOGIA

Italy

KAROLINSKA INSTITUTET

Sweden

KLINIKUM DER JOHANN WOLFGANG GOETHE UNIVERSITAET FRAUENKLINIK

Germany

MAASTRICHT UNIVERSITY / RESEARCH INSTITUTE GROWTH AND DEVELOPMENT

Netherlands

MARMARA UNIVERSITY MEDICAL SCHOOL HOSPITAL

Turkey

MARTIN LUTHER UNIVERSITÄT HALLE - WITTENBERG

Germany

MEDICAL UNIVERSITY OF GDANSK

Poland

N. N. BLOKHIN CANCER RESEARCH CENTER

Russia

NATIONAL AND KAPODISTRIAN UNIVERSITY OF ATHENS - GREECE

Greece

PORTUGUESE INSTITUTE OF ONCOLOGY FRANCISCO GENTIL - PORTO CENTER

Portugal

ST VINCENTS UNIVERSITY HOSPITAL

Ireland

SWISS INSTITUTE OF BIOINFORMATICS

Switzerland

TECHNICAL UNIVERSITY OF MUNICH

Germany

THE BANK OF CYPRUS ONCOLOGY CENTRE

Cyprus

THE CHANCELLORS, MASTERS AND SCHOLARS OF THE UNIVERSITY OF OXFORD

United Kingdom

THE NETHERLANDS CANCER INSTITUTE/ANTONI VAN LEEUWENHOEK HOSPITAL

Netherlands

THE UNIVERSITY OF EDINBURGH

United Kingdom

THE UNIVERSITY OF GLASGOW

United Kingdom

UNIVERSITAETSKLINIKUM EPPENDORF, KLINIK UND POLIKLINIK FUER GYNAEKOLOGIE

Germany

UNIVERSITY OF DUNDEE

United Kingdom

UNIVERSITY OF WALES, SWANSEA

United Kingdom

UNIVERSITÄTSKLINIKUM KÖLN (AÖR)

Germany

WEST GERMAN STUDY GROUP

Germany

Project information

Grant agreement ID: 503426

  • Start date

    1 March 2004

  • End date

    28 February 2011

Funded under:

FP6-LIFESCIHEALTH

  • Overall budget:

    € 23 171 000

  • EU contribution

    € 7 000 000

Coordinated by:

BREAST INTERNATIONAL GROUP-AISBL

Belgium